-
Telmisartan: A Causal Map for Cardiac Hypertrophy
2026-10-01
Telmisartan is an angiotensin II receptor antagonist that can anchor mechanistic cardiac hypertrophy experiments at the AT1 receptor. This guide shows how to use receptor blockade, RIP3/CaMKII readouts, and orthogonal pathway assays to distinguish upstream causality from downstream remodeling.
-
Amikacin (BAY416651): Assay Design Guide
2026-10-01
Amikacin (BAY416651) is more than a conventional aminoglycoside test compound. This guide shows how to connect its ribosomal mechanism, resistance profile, formulation behavior, and granuloma-delivery evidence to more informative antibiotic resistance research assays.
-
BMS-345541: IKK-1/IKK-2 Inhibitor Workflows
2026-09-30
BMS-345541 is a selective IKK-1/IKK-2 inhibitor for dissecting NF-κB-dependent cytokine signaling, endothelial responses, and cancer-cell phenotypes. This practical guide translates pathway evidence into assay-ready workflows, controls, optimization steps, and troubleshooting strategies.
-
ICAA Targets RIP3 in Ang II–Induced Cardiac Hypertrophy
2026-09-30
The 2026 reference study identifies isochlorogenic acid A (ICAA) as a direct regulator of RIP3 in angiotensin II- and pressure overload-induced cardiac hypertrophy. Its findings place the RIP3/CaMKII axis, rather than the canonical RIP3/MLKL pathway, at the center of ICAA-associated cardioprotection and provide a mechanistic framework for cardiovascular disease research.
-
Vitamin C Workflows for Senescence and Cancer
2026-09-29
Build reproducible ascorbic acid workflows for oxidative-stress, senescence, and cancer models. This guide connects the HEI-OC1 ROS/NF-κB study with dose-aware tumor-cell assays, fresh-solution handling, orthogonal readouts, and practical troubleshooting.
-
Neomycin sulfate: RNA, DNA, and Channel Workflows
2026-09-29
Neomycin sulfate is an aminoglycoside antibiotic repurposed as a mechanistic probe for hammerhead ribozymes, HIV-1 TAR recognition, DNA triplexes, and ryanodine receptor channels. This workflow-focused guide translates its binding and channel-blocking behavior into practical assay design, controls, and troubleshooting strategies.
-
Iptacopan Monotherapy in PNH: Phase 2 Evidence
2026-09-28
This open-label phase 2 proof-of-concept study examined oral factor B inhibition with Iptacopan (LNP023) as single-agent treatment for paroxysmal nocturnal hemoglobinuria (PNH). At the interim analysis, all 12 patients evaluable for efficacy met the week-12 lactate dehydrogenase response endpoint, with improvements in hemolysis markers and hemoglobin and reduced transfusion need; the small, uncontrolled study supports further testing rather than comparative conclusions.
-
(S)-(+)-Ibuprofen: COX Inhibitor Workflows
2026-09-27
Use the active ibuprofen enantiomer to test cyclooxygenase-linked prostaglandin responses with a dose-controlled, vehicle-matched workflow. Practical guidance covers assay setup, interpretation, and common solubility and reproducibility issues—without treating modest COX preference as isoform selectivity.
-
DiscoveryProbe Stem Cell Compound Library Plus: Workflow
2026-09-26
Turn stem-cell pathway coverage into a practical phenotypic-screening workflow, from assay design to orthogonal hit confirmation. A schistosome study shows how quantitative imaging can expose effects that simple morphology may miss—while underscoring the need to validate every hit in the intended model.
-
Iptacopan Assays: Reading Complement Inhibition
2026-09-26
Iptacopan (LNP023) provides a selective way to probe factor B and alternative-pathway amplification. This guide connects its mechanism to assay selection, control design, and interpretation—helping researchers distinguish target engagement from downstream complement effects.
-
AP1903: A Framework for Causal Assay Design
2026-09-25
AP1903 is an FKBP-binding ligand for conditional control of engineered proteins, but its greatest experimental value depends on how carefully activation is separated from expression and phenotype. This article connects AP1903 assay design to a multiplexed SARS-CoV-2 receptor study, showing how to interpret perturbation and compatibility data without conflating distinct biological questions.
-
HRP Goat Anti-Rabbit IgG: From Signal to Mechanism
2026-09-25
See how Affinity-Purified Goat Anti-Rabbit IgG (H+L) supports interpretable immunoassays in osteoarthritis research. Using a recent wogonin study as a case study, this article connects secondary-antibody selection to the strength and limits of mechanistic evidence.
-
Cy3 RNA Labeling Kit: HyperScribe™ T7 Workflow
2026-09-24
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus generates fluorescent RNA probes by in vitro transcription with Cy3-UTP, for workflows such as in situ hybridization and Northern blot hybridization. It is for research use only and is not intended for diagnostic, therapeutic, or clinical applications.
-
CFDA-SE Workflows for Proliferation and Migration
2026-09-24
CFDA-SE gives viable cells a division-sensitive fluorescent label that can support proliferation assays and migration studies when paired with the right controls. This practical workflow explains how to optimize staining and interpret it alongside, but not as a substitute for, CD38 surfaceome analysis.
-
EGCG Nanoparticles Boost FLASH Radioimmunotherapy
2026-09-23
Xu and colleagues developed functionalized self-assembled EGCG nanoparticles, termed BENPs, to increase tumor-cell sensitivity to FLASH radiotherapy while retaining its normal-tissue rationale. In a 4T1 breast cancer model, BENPs enhanced oxidative and DNA damage, increased tumor-cell death, and promoted antitumor immune features, although additional mechanistic and translational validation is needed.